netupitant + palonosetron

**Netupitant + palonosetron** is an oral fixed-dose antiemetic combination marketed as **Akynzeo**. It contains netupitant, a selective substance P/neurokinin-1 receptor antagonist, and palonosetron, a serotonin 5-HT3 receptor antagonist. By blocking complementary emetic signaling pathways involved in acute and delayed chemotherapy-induced nausea and vomiting, the combination provides single-dose prophylaxis before emetogenic chemotherapy. The oral product contains netupitant 300 mg and palonosetron 0.5 mg in a hard capsule and is approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205718s002lbl.pdf))

Brand names

Akynzeo

Other names

NEPAnetupitant + palonosetronnetupitant/palonosetron奈妥匹坦 + 帕洛诺司琼